Cargando…
LIFITEGRAST 5% FOR DRY EYE DISEASE: COMBINED EFFICACY AND SAFETY FROM FIVE RANDOMIZED CONTROLLED TRIALS
Five randomized, double-masked, placebo-controlled trials were conducted in the US in adults with DED, an eye dryness score (EDS, visual analogue scale [VAS], 0–100) ≥40, and inferior corneal staining score ([ICSS], 0-4) ≥2.0 at study entry: four 84-day efficacy trials (phase 2, lifitegrast n=58, pl...
Autores principales: | Gonzalez, Agustin L, Donnenfeld, Eric, Baudouin, Christophe, Holland, Edward, Nichols, Kelly, Karpecki, Paul, Hamdani, Mohamed, Shojaei, Amir |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6846150/ http://dx.doi.org/10.1093/geroni/igz038.983 |
Ejemplares similares
-
Safety and tolerability of lifitegrast ophthalmic solution 5.0%:
Pooled analysis of five randomized controlled trials in dry eye
disease
por: Nichols, Kelly K, et al.
Publicado: (2018) -
Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study
por: Donnenfeld, Eric D., et al.
Publicado: (2016) -
Reduction of Artificial Tears and Use of Adjunctive Dry Eye Therapies After Lifitegrast Treatment: Evidence from Clinical and Real-World Studies
por: Nichols, Kelly K, et al.
Publicado: (2022) -
PREDICTORS OF SHORTNESS OF BREATH DURING STAIR CLIMB IN COMMUNITY-DWELLING INDIVIDUALS WITH COPD
por: Gore, Shweta
Publicado: (2019) -
SLEEP APNEA ASSOCIATED COMORBIDITIES AND MORTALITY IN AN OLDER VETERAN POPULATION
por: Kresevic, Denise M, et al.
Publicado: (2019)